“After over two decades of scant effectiveness against cancer, oncolytic viruses could be close to finding their place in immuno-oncology combination regimens, where they could both be potentiated by and improve response rates to checkpoint agents.”
Read Emily Cukier-Meisner’s cover story for BioCentury “Infectious Enthusiasm” here: